| Today's Top Story |  |  | | - BIO, ASTA developing guidelines on biotech trait patent losses
BIO and the American Seed Trade Association are working on a road map for how to handle the patent expirations of biotech traits, beginning with Monsanto's Roundup Ready 1 in soybeans in April 2015. The agreement will help tech providers convey regulatory data from patent owners to seed companies, according to BIO's Matthew O'Mara and ASTA's Bernice Slutsky. Iowa Farmer Today (1/12)        |  |  | | See how Cardmembers use American Express OPEN Cards to help run their business:
“My business switched to paying bills with the Plum Card. The flexibility of having 2 months to pay my balance without interest when cash flow is tight is a major relief to me as a small business owner.” - Vishal V Patel, First Med Family Healthcare
With The Plum Card from American Express OPEN, you get the payment flexibility you need to help power your business.
LEARN MORE & APPLY | |  |  |  |
  - 3-way deal seeks to develop companion test for Pfizer's Xalkori
Pfizer, Roche Holding unit Ventana Medical Systems and Cell Signaling Technology formed a three-way partnership for a diagnostic test to be used with Xalkori, a recently FDA-approved drug for nonsmall-cell lung cancer. Ventana will create the immunohistochemistry-based device using CST technology to identify patients with ALK gene rearrangement. PMLive.com (U.K.) (1/12) - Survey: Few drugmakers say they're ready for generic competition
This year's patent losses are projected to cost drugmakers almost $29 billion in U.S. revenue, but only 17% of pharmaceutical and health care executives polled by The Economist Intelligence Unit think the sector is prepared for this challenge. Drug sales in Europe will decrease marginally for the fourth consecutive year, The Economist predicted. InPharm.com (1/12) - Study IDs gene linked to inherited prostate cancer
Research in the New England Journal of Medicine found that men with a mutation in the HOXB13 gene mutation are up to 20 times more likely to develop prostate cancer. The study could help determine which men need early screening. Researchers analyzed the DNA of 94 families and found the HOXB13 mutation was shared by four of them. A broader analysis showed the mutation was more common among men with a family history of the illness or early onset. HealthDay News (1/11)  | PAT in Green Chemistry and Green Engineering
This webinar shows how process analytical technologies and synthesis workstations in chemical reaction and crystallization design meet Green Chemistry and Engineering principles — minimizing waste, improving reaction output and decreasing by-product formation. Register for the webinar. |
 - Onyx's drug candidates might attract acquirers, CFO says
Onyx Pharmaceuticals has several products that might be approved within a year, making the drugmaker an attractive target for acquisition, said Chief Financial Officer Matt Fust. Last year, Onyx reportedly explored strategic alternatives, including a company sale. Bloomberg (1/12) - Epizyme reaches $4M milestone for cancer drugs
Epizyme secured $4 million in preclinical milestone fees from Eisai as part of their development and commercialization agreement on drugs targeting epigenetic enzyme EZH2 for the treatment of genetically defined cancers and lymphoma. The deal, signed last year, could give Epizyme more than $200 million in total milestones and royalties. Mass High Tech (Boston) (1/10) - N.C. Biotech Center grants $250,000 loan to Heat Biologics
Heat Biologics secured a $250,000 loan from the North Carolina Biotechnology Center to fund clinical development of cancer vaccines based on its proprietary Immune Pan-Antigen Cytotoxic Therapy. The firm is conducting Phase II studies for vaccine candidate HS-110 for the treatment of nonsmall-cell lung cancer. Additional trials for bladder and ovarian cancer are planned for this year. MedCityNews.com (1/12) - Grant program aims to further next-generation genome sequencing
GenomeQuest will provide a total of $120,000 worth of software, annotation data and infrastructure to six diagnostic laboratories to process and store next-generation sequencing data, produce reports and follow up on results. The program is intended to accelerate diagnostic tests for genetic disorders and bacterial pathogens. "The application of NGS to interrogate many genes simultaneously provides a major advance in clinical diagnostic testing that will benefit patients from a wide range of clinical services," said Edward Ginns, director of the Molecular Diagnostics Laboratory at UMass Memorial Medical Center, which received one of the grants. Genetic Engineering & Biotechnology News (1/11)  | Enterprise Resource Planning automates many aspects of an organization's operations, cascading across traditional boundaries of operations, finance, manufacturing and more. As such, changes in the ERP market can cause a ripple effect in your business. Get ahead of the changing tide and trends by downloading this free whitepaper. |
| Industrial & Environmental | | | | | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | Even the most tedious chore will become endurable as you parade through each day convinced that every task, no matter how menial or boring, brings you closer to fulfilling your dreams."
--Og Mandino,
American author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, January 12, 2012
- Wednesday, January 11, 2012
- Tuesday, January 10, 2012
- Monday, January 09, 2012
- Friday, January 06, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment